Similar Posts
Boosters for care home residents
All residents in care homes for older people will receive an additional Covid booster jab this spring, PM Boris Johnson said last week, setting out the government’s plan for living with the virus. But Alzheimer’s Society responded that the plan did not go far enough to protect people with dementia. While details of the additional…
Alzheimer’s Society publish data on delayed hospital discharges for people with dementia
The Alzheimer’s Society has published data showing that almost a third of people aged 65 and over who are fit to be discharged from hospital are remaining as inpatients for at least three weeks longer than necessary, with this almost 29,000 people (in one year) believed to have dementia. The figures come from NHS England…
Spotlight on local priorities
Registration is now open for the Alzheimer’s Society Annual Conference, which returns for 2023 during Dementia Action Week. The conference will put a spotlight on making dementia a priority locally, bringing together local leaders in dementia from across the UK to share best practice and challenges, and progress towards aims and ambitions in diagnosis and…
Centre for Ageing Better publish ‘Age-friendly Town and Parish Guide’
The Centre for Ageing Better has published the ‘Age-friendly Town and Parish Guide’. The guide covers local councils’ responsibilities, activities and influencing roles, case studies, mapping and action tools. It includes references to dementia-friendly initiatives and is endorsed by the National Association of Local Councils and the Society of Local Council Clerks. The guide can be read/downloaded…
E-learning: reflective practice
A new e-learning programme called “Care As You Are” is designed as a new approach to skills and practice development for staff in care and health organisations. The aim is to develop reflective practice as a way to provide emotional support to family carers of people living with dementia. The programme endeavours to go beyond…
New drug announced
Just a few months after the announcement of lecanemab as a drug for slowing Alzheimer’s progression, a second new drug has been announced by pharmaceutical firm Eli Lilly. Called donanemab, it is also a monoclonal antibody drug for removing amyloid protein that builds up in the brain as Alzheimer’s disease progresses. In people with mild…